1167055-68-6

Basic information

• Product Name: 2-Methyl-4-(broMoMethyl)pyridine hydrobroMide
• Synonyms: 2-Methyl-4-(broMoMethyl)pyridine hydrobroMide;2-Methyl-4-(bromomethyl)pyridine;4-(Bromomethyl)-2-methylpyridine hydrobromide
• CAS NO: 1167055-68-6
• Molecular Formula: C7H9Br2N
• Molecular Weight: 266.96106
• Mol File: 1167055-68-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 2-Methyl-4-(broMoMethyl)pyridine hydrobroMide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-4-(broMoMethyl)pyridine hydrobroMide(1167055-68-6)
• EPA Substance Registry System: 2-Methyl-4-(broMoMethyl)pyridine hydrobroMide(1167055-68-6)

Safety Data

• Hazardous Substances Data: 1167055-68-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-4-(bromomethyl)pyridine hydrobromide is used as a key intermediate in the synthesis of propargyl pyridinyl ethers. These ethers have potential applications as inhibitors of cytochrome P450, a group of enzymes that play a crucial role in the metabolism of drugs and other substances in the body. By inhibiting these enzymes, propargyl pyridinyl ethers can potentially improve the efficacy and safety of certain medications.
2-Methyl-4-(bromomethyl)pyridine hydrobromide is also used in the preparation of 4-azaindole derivatives. These derivatives have been identified as muscarinic M1 receptor modulators, which can be utilized in the treatment of cognitive deficits. The muscarinic M1 receptor is a target for various therapeutic interventions, particularly in the treatment of Alzheimer's disease and other cognitive disorders. By modulating the activity of this receptor, 4-azaindole derivatives can potentially enhance cognitive function and improve the quality of life for patients suffering from these conditions.

Upstream product

• 108-47-4 2,4-lutidine 
• 105250-16-6 (2-methylpyridin-4-yl)methanol 

Downstream Products

• 165558-79-2 methyl<(2-methylpyridin-4-yl)methyl>amine 

Relevant articles and documents

Regioselectivity in free radical bromination of unsymmetrical dimethylated pyridines

During a literature review some curious inconsistencies in the free radical bromination of picolines were noted. To achieve a better understanding of the mechanisms and regioselectivity we reran these reactions, extending our work to unsymmetrical lutidin

PYRIDOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Synthesis and Biological Evaluation of Novel 2,6-Diaminobenzindole Inhibitors of Thymidylate Synthase Using the Protein Structure as a Guide

The design, synthesis, and biochemical and biological evaluations of a novel series of 2,6-diaminobenzindole-containing inhibitors of human thymidylate synthase (TS) are described.The compounds are characterized by having either a pyridine or pyridazine ring in place of the (phenylsulfonyl)morpholinyl group of the known inhibitor N6--N6-methyl-2,6-diaminobenzindole glucuronate (i).Active compounds from this series showed human TS inhibition constants below the 10 nM level and were potent, selective submicromolar antitumor agents in cell culture.The compounds were synthesized by reductive alkylation of a substituted 6-aminobenzindole or reductive cyclization of a substituted 1-cyano-8-nitronaphthalene.